Journal
NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 17, Issue 9, Pages 1088-U8Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb.1869
Keywords
-
Funding
- US National Institutes of Health (NIH) [AI035726, AI034343, AI069085, HL055967, AI027243, AI071155, AI049313, AI068135]
- Robert A. Welch Foundation
- Cancer Research Institute
- American Lung Association [RG48786N]
- Burroughs Wellcome Fund for Translational Research
- NIH [AI067093]
Ask authors/readers for more resources
Knockout of lprG results in decreased virulence of Mycobacterium tuberculosis (MTB) in mice. MTB lipoprotein LprG has TLR2 agonist activity, which is thought to be dependent on its N-terminal triacylation. Unexpectedly, here we find that nonacylated LprG retains TLR2 activity. Moreover, we show LprG association with triacylated glycolipid TLR2 agonists lipoarabinomannan, lipomannan and phosphatidylinositol mannosides (which share core structures). Binding of triacylated species was specific to LprG (not LprA) and increased LprG TLR2 agonist activity; conversely, association of glycolipids with LprG enhanced their recognition by TLR2. The crystal structure of LprG in complex with phosphatidylinositol mannoside revealed a hydrophobic pocket that accommodates the three alkyl chains of the ligand. In conclusion, we demonstrate a glycolipid binding function of LprG that enhances recognition of triacylated MTB glycolipids by TLR2 and may affect glycolipid assembly or transport for bacterial cell wall biogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available